UBS analyst Trung Huynh raised the firm’s price target on Regeneron to $1,250 from $1,124 and keeps a Buy rating on the shares as part of a Q2 earnings preview for the U.S. pharmaceuticals group. The firm is 2% higher than consensus on Regeneron’s Q2 sales due to higher Dupixent expectations. It expects Eylea HD performance will remain a focus for investors, along with recent obesity data.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $1,182 from $1,183 at Morgan Stanley
- Regeneron price target raised to $1,200 from $1,050 at Barclays
- Regeneron, Sanofi announce EC approval for Dupixent
- Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
- Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma